DESCRIPTION
IDENTIFYING TRANSACTIONAL OPPORTUNITIES IN A CAPITAL CONSTRAINED MARKET: HOW TO WIN
Institutional and strategic investors have triaged their existing portfolios to identify winners and losers. How will the winners be supported going forward? Will the losers be sold, partnered, put in hibernation or taken over by co-investors? After focusing on their existing portfolios, some investors are now looking externally for potential winners. The financial crisis did not alter the pace of medical innovation and healthcare reform might introduce a host of new opportunities. Who are the buyers, what are they looking for and how are they structuring their deals to assure success? Our panel will address these questions, and yours, with reference to early-stage and late-stage companies.
SPEAKERS:
-
Richard S. Lukaj
, Senior Managing Director, Bank Street
-
-
Ankit Mahadevia, M.D., MBA, Atlas Venture, Life Sciences Sector
-
Joel Braunstein, M.D., MBA, Co-founder and President, LifeTech Research and Founding CEO and President, Centegen, Inc.
OPPORTUNITIES AND THREATS FROM HEALTH CARE REFORM
Presented by Tom Barker, Foley Hoag LLP
Some version of health care reform legislation is almost certain to be enacted before year's end and Congress is now in the thick of the debate. Who will be the winners and losers in the health care reform debate? Pharmaceutical manufacturers, the White House and the Senate have reached agreement on key issues: how will that agreement be implemented? Will it hold through the legislative process or do manufacturers face additional challenges? The medical device sector is facing a new tax regime - will it survive the legislative process? Insurers face new regulations and potentially new premium taxes. Traditional health care providers - hospitals, nursing facilities, home health agencies - will also be asked to contribute to the cost of health care reform. What will their burden be? Our speaker will take us through the various industry sectors that will be affected by health care reform, describe the current state of the legislation and the threats to these sectors, and predict a likely final outcome of the debate.
THERAPEUTIC AREAS MOST LIKELY TO WIN: NEUROLOGY AND CANCER
Neurology: Multiple Sclerosis
Will new emerging therapies change the treatment paradigm in Multiple Sclerosis? With the potential approval of new oral therapies in development, neurologists will have new treatment modalities. This panel will discuss the regulatory environment for the leading oral agents in development, and whether the risk-benefit profile warrants first-line use. The panel will also discuss promising early-stage targets in this indication that have the potential to revolutionize therapy.
Cancer: Accelerating Drug Development with Biomarkers
This panel will discuss the future of biomarkers in cancer as it relates to the increasing requirement of a companion diagnostic linked to drug development and approval. Gains from increasing specificity in treating patients will support greater efficacy, reduce adverse events, and save the healthcare system significant amounts of tax-payer dollars. How these gains translate to everyday medicine will be linked to biomarker stratification within therapeutic indications, as well as to how personalized medicine is likely to move forward using the recent KRAS mutation in colorectal cancer as a model.
MODERATOR:
Kimberly Ha, Deputy Editor, Pharmawire
SPEAKERS:
-
Dr. Andrew L. Pecora, M.D. FACP, CPE, Chairman and Executive Administrative Director, John Theurer Cancer Center at Hackensack University Medical Center
-
Dr. Rip Kinkel, M.D., Director, Multiple Sclerosis Center at the Beth Israel Deaconess Medical Center
-
Dr. Daniel Kantor, Medical Director, Neurologique Foundation in Florida, and an investigator on numerous trials in multiple sclerosis
-
Les Funtleyder, Healthcare Strategist, Miller Tabak + Co., LLC and Portfolio Manager of the Miller Tabak Health Care Opportunities Fund
-
Dr. Louis Matis, President and CEO, Immune Tolerance Institute
COST: Free